Substituted amide derivatives and methods of use

Details Substituted amide derivatives and methods of use Substituted amide derivatives and methods of use

2006-04-26

2010-12-28

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S130000

Reexamination Certificate

active

07858623

ABSTRACT:
Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

REFERENCES:
patent: 3755332 (1973-08-01), Wasley et al.
patent: 4916135 (1990-04-01), Effland et al.
patent: 5580870 (1996-12-01), Barker et al.
patent: 5866572 (1999-02-01), Barker et al.
patent: 5965563 (1999-10-01), Buzzetti et al.
patent: 6143764 (2000-11-01), Kubo et al.
patent: 6265398 (2001-07-01), Braun et al.
patent: 6313129 (2001-11-01), Uckun et al.
patent: 6358962 (2002-03-01), Uckun et al.
patent: 6399602 (2002-06-01), Barker et al.
patent: 6469013 (2002-10-01), Uckun et al.
patent: 6495556 (2002-12-01), Uckun et al.
patent: 6573289 (2003-06-01), Tasaka et al.
patent: 6897214 (2005-05-01), Barker et al.
patent: 2003/0165873 (2003-09-01), Come et al.
patent: 2004/0242603 (2004-02-01), Fujiwara et al.
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0209905 (2004-10-01), Kubo et al.
patent: 2005/0245547 (2005-11-01), Kim et al.
patent: 860433 (1998-08-01), None
patent: 1411046 (2004-04-01), None
patent: 1415987 (2004-05-01), None
patent: 1 548 008 (2005-06-01), None
patent: 8-193070 (1996-07-01), None
patent: 63-145272 (1998-06-01), None
patent: 11-158149 (1999-06-01), None
patent: WO 96/23774 (1996-08-01), None
patent: WO 96/29301 (1996-09-01), None
patent: WO 96/29305 (1996-09-01), None
patent: WO 97/03069 (1997-01-01), None
patent: WO97/22596 (1997-06-01), None
patent: WO 98/37079 (1998-08-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/54309 (1999-10-01), None
patent: WO 99/61428 (1999-12-01), None
patent: WO 00/10981 (2000-03-01), None
patent: WO 00/47212 (2000-08-01), None
patent: WO00/50405 (2000-08-01), None
patent: WO 00/56720 (2000-09-01), None
patent: WO 00/61580 (2000-10-01), None
patent: WO 01/21594 (2001-03-01), None
patent: WO 01/70673 (2001-09-01), None
patent: WO 01/70734 (2001-09-01), None
patent: WO 02/22607 (2002-03-01), None
patent: WO 02/22608 (2002-03-01), None
patent: WO 02/30924 (2002-04-01), None
patent: WO 02/076976 (2002-10-01), None
patent: WO02/098426 (2002-12-01), None
patent: WO03/004472 (2003-01-01), None
patent: WO 03/040108 (2003-05-01), None
patent: WO 03/040109 (2003-05-01), None
patent: WO 03/064413 (2003-08-01), None
patent: WO 03/082272 (2003-10-01), None
patent: WO2004/018430 (2004-03-01), None
patent: WO 2004/029045 (2004-04-01), None
patent: WO2004/030672 (2004-04-01), None
patent: WO2004/037784 (2004-05-01), None
patent: WO2004/043379 (2004-05-01), None
patent: WO2004/046133 (2004-06-01), None
patent: WO 2004/078114 (2004-09-01), None
patent: WO2004/083235 (2004-09-01), None
patent: WO 2004/085425 (2004-10-01), None
patent: WO 2004/098604 (2004-11-01), None
patent: WO 2005/005389 (2005-01-01), None
patent: WO2005/021553 (2005-03-01), None
patent: WO2005/030140 (2005-04-01), None
patent: WO2005/037285 (2005-04-01), None
patent: WO2005/070891 (2005-08-01), None
patent: WO2005/080377 (2005-09-01), None
patent: WO 2005/117867 (2005-12-01), None
patent: WO 2006/004636 (2006-01-01), None
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247.
Machine translation of “Detailed Description” for JP 08-193070, translated Jan. 26, 2010.
Anderson et al., “Involvement of the protein tyrosine kinase p56kkin T cell signaling and thymocyte development,” Advances in Immunology, 56:151-178 (1994).
Appleby et al., “Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn”,Cell, 70:751-763 (1992).
Asami et al., “Purification and characterization of hepatocyte growth factor from injured liver of carbon tetrachloride-treated rats,” Journal of Biochemistry, 109:8-13 (1991).
Asano et al., “Silver halide color photographic materials,” Abstract 113:181318 (1990).
Boehm et al., “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance,” Nature, 390:404-407 (1997).
Bolen et al., “Leukocyte protein tyrosine kinases: Potential targets for drug discovery,” Annu. Rev. Immunology, 15:371-404 (1997).
Bussolino et al., “Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth,” The Journal of Cell Biology, 119(3):629-641 (1992).
Chan et al., “Isoforms of human HGF and their biological activities,” Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-MetReceptor, pp. 67-79, Goldberg and Rosen (Eds.), Birkhauser Verlag Basel, Switzerland (1993).
Chatterjee, A.K., “A note on 4-Aminoquinolines. III. Some 4-(quinolylamino)quinolines,” Science and Culture 23:195 (1957).
Cockerill et al., “Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2,” Bioorganic & Medicinal Chemistry Letters, 11:1401-1405 (2001).
Di Renzo et al., “Selective expression of theMet/HGF receptor in human central nervous system microglia, Oncogene,” 8:219-222 (1992).
Gibson et al., “Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumor activity of novel quinazolines,” Bioorganic & Medicinal Chemistry Letters, 7(21):2723-2728 (1997).
Giordano et al., “Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of humanMETprotooncogene,” Proceedings of the National Academy of Sciences, USA, 90:649-653 (1993).
Goldman et al, “Defective expression of p56lck in an infant with severe combined immunodeficiency, ” Journal of Clinical Investigations, 102(2):421-429 (1998).
Han et al., “Characterization of the DNF15S2 locus on human chromosome 3: Identification of a gene coding for four kringle domains with homology to hepatocyte growth factor,” Biochemistry, 30:9768-9780 (1991).
Igawa et al., “Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells,” Biochemical and Biophysical Research Communications, 174(2):831-838 (1991).
Jeffers et al., “Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis,” J. Mol. Med., 74:505-513 (1996).
Kane et al., “Signal transduction by the TCR for antigen,” Current Opinion in Immunology, 12:242-249 (2000).
Kasai et al., “Flexible coordination networks with fluorinated backbones, remarkable ability for induced-fit enclathration of organic molecules,” Journal of American Chemical Society, 122:2140-2141 (2000).
Lempert-Sreter et al., “The synthesis of di(1-isoquinolinyl) and di(4-quinazolinyl) disulfides form 1(2H)-isoquinolinethiones and 4(3H)-quinazolinethiones, respectively, with tosyl chloride and sodium ethoxide,” Acta Chemica Hungarica, 112(1):83-87 (1983).
Makisumi, Yasuo, “The Thio-claisen rearrangement of allyl 4-quinolylsulfides,” Tetrahedron Letters, 51:6399-6403 (1966).
Maslankiewicz, M.J., “Reactions of β- and γ-quinolinyl sulfides with a nitrating mixture,” Polish Journal of Chemistry, 68(12):2545-2552 (1994).
Matsumoto et al., “Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth,” Biochemical and Biophysical Research Communications, 176(1):45-51 (1991).
Matsunaga et al., “C17,20-lyase inhibitors. Part 2:Design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-Iyase inhibitors,” Bioorganic & Medicinal Chemistry, 12:4313-4336 (2004).
Maulik et al., “Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibit

Affiliated with

Also associated with

Rating

Substituted amide derivatives and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted amide derivatives and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted amide derivatives and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4195329